Arcellx, Inc. (NASDAQ:ACLX) Shares Sold by Voya Investment Management LLC

Voya Investment Management LLC lowered its position in Arcellx, Inc. (NASDAQ:ACLX - Free Report) by 7.1% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 136,203 shares of the company's stock after selling 10,445 shares during the period. Voya Investment Management LLC owned 0.25% of Arcellx worth $10,445,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Headlands Technologies LLC purchased a new stake in shares of Arcellx in the fourth quarter worth about $41,000. KBC Group NV increased its position in shares of Arcellx by 37.3% during the fourth quarter. KBC Group NV now owns 1,388 shares of the company's stock valued at $106,000 after acquiring an additional 377 shares in the last quarter. Avanza Fonder AB bought a new position in shares of Arcellx during the fourth quarter valued at $184,000. Kazazian Asset Management LLC purchased a new position in shares of Arcellx during the fourth quarter valued at approximately $204,000. Finally, Landscape Capital Management L.L.C. bought a new stake in shares of Arcellx in the fourth quarter worth $214,000. Institutional investors own 96.03% of the company's stock.

Arcellx Price Performance

Shares of ACLX stock traded up $0.02 on Friday, hitting $65.55. 305,387 shares of the stock traded hands, compared to its average volume of 552,632. The firm has a 50 day simple moving average of $64.90 and a two-hundred day simple moving average of $74.05. The firm has a market cap of $3.61 billion, a price-to-earnings ratio of -92.32 and a beta of 0.33. Arcellx, Inc. has a 52 week low of $47.88 and a 52 week high of $107.37.

Arcellx (NASDAQ:ACLX - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by ($0.24). Arcellx had a negative return on equity of 8.28% and a negative net margin of 25.94%. The business had revenue of $15.27 million for the quarter, compared to the consensus estimate of $27.42 million. Sell-side analysts forecast that Arcellx, Inc. will post -1.58 EPS for the current year.

Insider Buying and Selling

In other news, insider Rami Elghandour sold 38,300 shares of the company's stock in a transaction dated Wednesday, February 26th. The shares were sold at an average price of $62.02, for a total value of $2,375,366.00. Following the completion of the sale, the insider now directly owns 149,186 shares of the company's stock, valued at approximately $9,252,515.72. This represents a 20.43 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Kavita Patel sold 1,500 shares of the business's stock in a transaction dated Tuesday, April 29th. The shares were sold at an average price of $64.20, for a total value of $96,300.00. The disclosure for this sale can be found here. Insiders sold 55,955 shares of company stock valued at $3,504,758 over the last quarter. 6.24% of the stock is currently owned by company insiders.

Arcellx Profile

Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).